
XNCR
Healthcare · Biotechnology · $2.78B market cap
$37.09-1.04 (-2.7%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -9.2% over 90 days · 30-day revisions 2 up, 3 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2026 | After the close | -0.35 | 0.50 | +242.9% |
| Aug 5, 2026 | After the close | -0.82 | -0.29 | +64.6% |
| May 6, 2026 | After the close | -0.75 | -1.71 | -128.0% |
| Mar 4, 2026 | Time not confirmed | -0.60 | -0.09 | +85.1% |
| Nov 5, 2025 | After the close | -0.72 | -0.08 | +88.9% |
| Aug 6, 2025 | After the close | -0.71 | -0.41 | +42.3% |
| May 7, 2025 | After the close | -0.58 | -0.66 | -13.8% |
| Feb 25, 2025 | Before the open | -0.79 | -0.62 | +21.1% |
| Nov 6, 2024 | After the close | -1.02 | -0.71 | +30.4% |
| Aug 5, 2024 | After the close | -0.79 | -1.07 | -35.4% |
| May 9, 2024 | After the close | -0.77 | -1.11 | -44.2% |
| Feb 27, 2024 | After the close | -0.09 | -0.31 | -244.4% |
| Nov 7, 2023 | After the close | -0.71 | -0.40 | +43.7% |
| Aug 3, 2023 | After the close | -0.81 | -0.37 | +54.3% |
| May 8, 2023 | After the close | -0.66 | -1.02 | -54.5% |
| Feb 23, 2023 | After the close | -0.81 | -0.20 | +75.3% |
| Nov 7, 2022 | After the close | -0.72 | -0.55 | +23.6% |
| Aug 3, 2022 | After the close | -0.47 | -0.57 | -21.3% |
| May 5, 2022 | After the close | -0.45 | 0.39 | +186.7% |
| Feb 23, 2022 | After the close | -0.10 | 1.21 | +1310.0% |
| Nov 8, 2021 | After the close | -0.70 | -0.69 | +1.4% |
| Aug 4, 2021 | After the close | -0.55 | 0.87 | +258.2% |
| May 5, 2021 | After the close | -0.67 | -0.04 | +94.0% |
| Feb 24, 2021 | Before the open | -0.46 | -0.24 | +47.8% |
| Nov 6, 2020 | Before the open | -0.22 | -0.22 | 0.0% |
| Aug 4, 2020 | After the close | -0.50 | -0.61 | -22.0% |
| May 7, 2020 | After the close | -0.41 | -0.14 | +65.9% |
| Feb 24, 2020 | After the close | -0.41 | -0.47 | -14.6% |
| Nov 5, 2019 | After the close | -0.53 | -0.18 | +66.0% |
| Aug 6, 2019 | After the close | -0.45 | -0.28 | +37.8% |
| May 9, 2019 | After the close | 0.09 | 1.38 | +1433.3% |
| Feb 25, 2019 | After the close | -0.49 | -0.32 | +34.7% |
| Nov 5, 2018 | After the close | -0.52 | 0.05 | +109.6% |
| Aug 6, 2018 | After the close | -0.57 | -0.46 | +19.3% |
| May 7, 2018 | After the close | -0.47 | -0.62 | -31.9% |
| Feb 27, 2018 | After the close | -0.35 | -0.25 | +28.6% |
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory…